DelveInsight’s, “Allergic Conjunctivitis Pipeline Insight 2023” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Allergic Conjunctivitis pipeline landscape. It covers the Allergic Conjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Allergic Conjunctivitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Allergic Conjunctivitis Pipeline Report

• DelveInsight’s Allergic Conjunctivitis pipeline report depicts a robust space with 22+ active players working to develop 22+ pipeline therapies for Allergic Conjunctivitis treatment.
• The leading companies working in the Allergic Conjunctivitis Market include Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, and others.
• Promising Allergic Conjunctivitis Pipeline Therapies in the various stages of development include NAABAK eyedrops, Saline eyedrops, Dexamethasone, Ketotifen, AL-38583 ophthalmic solution, and others.
• March 2023: Faes Farma S.A. announced a study of phase 3 clinical trials for Bilastine Ophthalmic Solution 0.6%. To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.
• September 2023: Bausch & Lomb Incorporated announced a study of phase 3 clinical trials for Ketotifen fumarate ophthalmic solution 0.035% and Brimonidine tartrate ophthalmic solution 0.025%. To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis.

 

Request a sample and discover the recent advances in Allergic Conjunctivitis Treatment Drugs @ Allergic Conjunctivitis Pipeline Report

 

In the Allergic Conjunctivitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Conjunctivitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Allergic Conjunctivitis Overview

Allergic conjunctivitis is a common, under-appreciated, and largely benign process. It is rarely vision-threatening but can significantly decrease the quality of life for patients. There are three subtypes of simple allergic conjunctivitis: acute, seasonal, and perennial. There is considerable overlap with atopic conjunctivitis (vernal and atopic keratoconjunctivitis) and giant papillary conjunctivitis in both treatment and certain aspects of pathophysiology.

 

Find out more about Allergic Conjunctivitis Therapeutics Assessment @ Allergic Conjunctivitis Preclinical and Discovery Stage Products

 

Allergic Conjunctivitis Emerging Drugs Profile

• Reproxalap: Aldeyra Therapeutics
• VSJ-110: Vanda Pharmaceuticals

 

Allergic Conjunctivitis Pipeline Therapeutics Assessment

There are approx. 22+ key companies which are developing the Allergic Conjunctivitis therapies. The Allergic Conjunctivitis companies which have their Allergic Conjunctivitis drug candidates in the most advanced stage, i.e. phase III include, Aldeyra Therapeutics.

 

Learn more about the emerging Allergic Conjunctivitis Pipeline Therapies @ Allergic Conjunctivitis Clinical Trials Assessment

 

Scope of the Allergic Conjunctivitis Pipeline Report

• Coverage- Global
• Allergic Conjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Allergic Conjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Allergic Conjunctivitis Companies- Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, Immunotek SL, Roxall Medicina España S.A, Biomay AG, and others.
• Allergic Conjunctivitis Pipeline Therapies- NAABAK eyedrops, Saline eyedrops, Dexamethasone, Ketotifen, AL-38583 ophthalmic solution, and others.

 

Dive deep into rich insights for new drugs for Allergic Conjunctivitis Treatment, Visit @ Allergic Conjunctivitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Allergic Conjunctivitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Allergic Conjunctivitis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Reproxalap: Aldeyra Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. VSJ-110: Vanda Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. IC 270: IACTA Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Allergic Conjunctivitis Key Companies
21. Allergic Conjunctivitis Key Products
22. Allergic Conjunctivitis- Unmet Needs
23. Allergic Conjunctivitis- Market Drivers and Barriers
24. Allergic Conjunctivitis- Future Perspectives and Conclusion
25. Allergic Conjunctivitis Analyst Views
26. Allergic Conjunctivitis Key Companies
27. Appendix

 

For further information on the Allergic Conjunctivitis Pipeline therapeutics, reach out to Allergic Conjunctivitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking